Holen Sie sich die Stockscreener-App
24.49
1.07%
0.26
Vorhandelsmarkt:
25.55
1.06
+4.33%
Schlusskurs vom Vortag:
$24.23
Offen:
$24.23
24-Stunden-Volumen:
1.89M
Relative Volume:
0.96
Marktkapitalisierung:
$2.49B
Einnahmen:
$139.74M
Nettoeinkommen (Verlust:
$-79.99M
KGV:
-24.11
EPS:
-1.0157
Netto-Cashflow:
$-360.05M
1W Leistung:
+2.77%
1M Leistung:
-7.72%
6M Leistung:
-2.55%
1J Leistung:
+60.07%
1-Tages-Spanne:
$23.44
$24.66
1-Wochen-Bereich:
$23.44
$25.30
52-Wochen-Spanne:
$13.54
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
24.49 | 2.49B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.
Beam Therapeutics CEO Sells Over $700K in Stock - National Today
Beam Therapeutics Insider Sells $146K in Shares - National Today
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock By Investing.com - Investing.com Australia
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares of Stock - MarketBeat
John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares - MarketBeat
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock By Investing.com - Investing.com Australia
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock - Investing.com
Beam Therapeutics president sells $290k in shares - investing.com
[Form 4] Beam Therapeutics Inc. Insider Trading Activity - stocktitan.net
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (BEAM) CMO covers tax obligations via 6,700-share sale - stocktitan.net
Beam Therapeutics (BEAM) SVP auto-sells shares to cover RSU tax obligations - stocktitan.net
Beam Therapeutics (BEAM) CLO auto-sells 5,956 shares for RSU tax withholding - stocktitan.net
Beam Therapeutics (BEAM) president’s 11,810-share sale covers RSU taxes - stocktitan.net
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
SG Americas Securities LLC Boosts Beam Therapeutics Stake by 139% - National Today
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics Inc. (BEAM) interactive stock chart - sg.finance.yahoo.com
Beam Therapeutics (NASDAQ: BEAM) awards 20,000 RSUs to Chief Legal Officer - stocktitan.net
Beam Therapeutics (BEAM) awards 20,000 RSUs to SVP Bethany Cavanagh - stocktitan.net
Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon - stocktitan.net
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs - stocktitan.net
Beam Therapeutics (BEAM) grants president 40,000 restricted stock units - stocktitan.net
Beam Therapeutics (BEAM): Among the stocks that could 10x over the next 5 years - MSN
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock - MarketBeat
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing - Moomoo
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam (BEAM) Reports Promising Data from BEACON Trial in Sickle C - GuruFocus
Beam Therapeutics publishes sickle cell therapy trial data By Investing.com - Investing.com Australia
Why Is BEAM Stock Edging Higher After Hours Today? - Stocktwits
Beam Therapeutics CEO Evans sells $1.1m in stock By Investing.com - in.investing.com
Beam Therapeutics CEO Evans sells $1.1m in stock - investing.com
Beam Therapeutics (BEAM) CEO sells 50K shares, gains 90K RSUs - stocktitan.net
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - The Manila Times
In 31 sickle cell patients, Beam saw no severe pain crises after risto-cel - stocktitan.net
[144] Beam Therapeutics Inc. SEC Filing - stocktitan.net
ETRADE Financial (NASDAQ: BEAM) insider sales and restricted vesting - stocktitan.net
BEAM (NASDAQ: BEAM) affiliate notifies sale of 25,000 shares via option exercise - stocktitan.net
Beam to advance gene-editing drug to pivotal development - MSN
BEAM (NASDAQ: BEAM) insider schedules 25,000-share sale after option exercise - stocktitan.net
Beam Therapeutics gains on clinical update as gene therapy hits protective protein levels - MSN
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):